arexvy rsv - Search News

News

GSK, RSV and EMA

Zacks Investment Research on M… · 8h

EMA Accepts GSK's Filing for Expanded Use of RSV Vaccine Arexvy

GSK plc GSK announced that the European Medicines Agency (EMA) has accepted the regulatory application seeking approval to expand the use of its adjuvanted recombinant respiratory syncytial virus (RSV) vaccine,

Medical Dialogues · 1d

GSK RSV vaccine Arexvy accepted for regulatory review by EMA to expand use in adults 18 years, older

London: GSK plc has announced that the European Medicines Agency (EMA) has accepted the company's regulatory application to expand the use of its adjuvanted recombinant respiratory syncytial

Reuters on MSN · 3d

GSK says EU regulator reviewing expanded use of RSV vaccine

GSK said on Friday the European Medicines Agency had accepted the drugmaker's application to expand the use of its respiratory syncytial virus (RSV) vaccine, Arexvy, to adults aged 18 and above. An expanded approval will help GSK better compete with rivals such as Merck's mRESVIA and Pfizer's Abrysvo after U.

Moderna's RSV shot gets US nod for use in younger adults

Pfizer's RSV shot Abrysvo was cleared by the FDA last October for the 18 to 59 age group, extending its 2023 approval in the ...

FDA clears Moderna’s RSV vaccine for use in people aged 18 to 59

The FDA expanded the approval of Moderna’s RSV vaccine, extending the license to include more adults and giving the company a ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results